Universal Quantum Announced a Series A of More Than $100 Million on 8 October 2026: What Published Cytochrome P450 Resource Estimates Say About Quantum Drug-Metabolism Chemistry
Universal Quantum funds trapped-ion machines with drug discovery in view
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 8 October 2026 the University of Sussex announced that its spin-out Universal Quantum had raised a Series A round of more than $100 million, co-led by Firgun Ventures and DCVC. The university calls it the largest Series A raised by a UK quantum company and the company's first significant institutional financing. Universal Quantum builds trapped-ion quantum computers from linked chip modules, and it lists drug discovery among the uses that larger, error-corrected machines could open up.
For readers in hospitals and pharmaceutical research, the useful question behind the money is how large a machine has to become before it can calculate something a medicinal chemist cannot already calculate on a classical computer. One published benchmark concerns the cytochrome P450 enzymes, which break down most medicines in the liver, and its estimate runs to millions of physical qubits on a generic error-corrected machine.
The university's announcement names further investors, among them the Singapore investor EDBI, Invus, Integral GlobalTech, Main Sequence, Hostplus, NGS Super and Roblox founder Dave Baszucki. Chief executive Sebastian Weidt, who co-founded the company with physicist Winfried Hensinger, said the round reflects investors' belief that Universal Quantum offers "one of the most credible paths to quantum computing at scale." The university states that the company now employs more than 100 people on three continents.
A trapped-ion computer holds single charged atoms in electric fields above a chip and uses each ion as a qubit. Most trapped-ion systems address their ions with many finely aimed laser beams. Universal Quantum follows the design that Hensinger and Weidt published in 2017 as a blueprint for a large machine, in which a global microwave field drives the qubit operations and local voltages select which ions respond. According to reporting by Tech.eu on the round, the company's chip carries hundreds of ion qubits on a die larger than 400 square millimeters and is made on a standard 200-millimeter commercial foundry line.
The harder engineering problem is connecting chips. In a paper in Nature Communications of 8 February 2023, Mamun Akhtar and colleagues in Hensinger's Sussex group moved ions physically from one chip module to the next at a rate of 2,424 transfers per second, with a probability below 7 in 100 million that an ion is lost during a transfer. Separately, the authors found no measurable loss of the qubits' phase coherence from the transport. That link is the basis of the modular, tileable machine the company wants to build. Tech.eu also reports a €67 million contract from the German Aerospace Center (DLR) in 2023 and a hub in Hamburg that the new money will expand, alongside growth in the United States and Japan.
Drug safety depends heavily on metabolism. A Google Research post by Nicholas Rubin and Ryan Babbush of 12 October 2023 notes that enzymes of the P450 family carry out more than 70 percent of all drug metabolism. When two drugs compete for the same P450 enzyme, levels of one can rise into a toxic range; when a patient's genes make an enzyme fast or slow, a standard dose can be too weak or too strong. Predicting how a new molecule binds and reacts at the iron center of these enzymes is therefore a real problem in pharmaceutical development.
QC Ware and IonQ Mapped Four Orbitals of a Cytochrome P450nor Active Site Onto Eight Qubits of IonQ Forte on 1 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
How tightly a candidate binds its target is one important factor in whether a drug works, and metal centers are among the difficult cases to calculate: an iron atom sitting in the middle of an enzyme. On 1 September 2026 QC Ware and IonQ said they had measured a four-orbital slice of one such site on a quantum computer and landed close to the classical answer. QC Ware's Promethium platform did the classical preparation, IonQ's Forte trapped-ion processor took the quantum measurement through Amazon Braket, and the target was the heme active site of cytochrome P450nor. The workflow calculated an electrostatic interaction energy within 0.5 kcal/mol of classical benchmarks, roughly four percent, inside the one kcal/mol threshold conventionally called chemical accuracy.
The IonQ half of a workflow already run on IBM hardware
This is a follow-up. On 7 August 2026 this Monitor read the same QC Ware Promethium workflow running a nitric oxide reductase calculation on IBM's 156-qubit Heron processor. The platform, the enzyme family and the hybrid division of labor are unchanged; the processor underneath is what is new, which makes hardware portability the company's actual claim. Portability is not comparability: the August disclosure carried no numerical result that today's figure could be set against. Today's release adds four disclosures the August account did not carry: the 115-atom active-site model, its more than 1,000 molecular orbitals, the reduction to a four-orbital active space mapped onto eight qubits, and the 0.5 kcal/mol comparison itself.
What the quantum machine actually did
The quantum step ran on eight qubits of a 36-qubit machine, measuring a four-orbital slice carved out of a model containing more than a thousand molecular orbitals. Promethium built the model, identified the strongly correlated region, reduced it automatically to that active space, and computed the final interaction energies classically after Forte measured the qubits in a single basis. Everything before and after the quantum slice happened on classical hardware.
Which enzyme, and why the framing needs care
P450nor sits in the cytochrome P450 superfamily whose monooxygenase members carry out most human drug metabolism, and the release says exactly that. P450nor itself is something else: a fungal CYP55 nitric oxide reductase, characterized in Fusarium oxysporum among other fungi, reducing nitric oxide to nitrous oxide and taking its electrons straight from reduced nicotinamide adenine dinucleotide, NADH. The release names no organism and no accession. It is a well-characterized computational test case, which is a good reason to choose it for a hardware demonstration and a poor reason to describe the run as modeling human drug metabolism.
What the result can and cannot establish
The comparison target was a classical benchmark, so the classical answer existed first, and the companies report agreement for this known case. The announcement names no preprint, reports no shot count, gives no uncertainty on the 0.5 kcal/mol figure and does not identify which classical method produced the benchmark.